Previous close | 967.80 |
Open | 964.40 |
Bid | 960.20 x 0 |
Ask | 966.20 x 0 |
Day's range | 964.40 - 964.40 |
52-week range | 627.50 - 970.40 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.